


**Company Registration No. 3500767**

**HAYS PHARMA CONSULTING LIMITED  
ANNUAL REPORT AND FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2016**



# **Hays Pharma Consulting Limited**

## **Annual Report and Financial Statements for the year ended 30 June 2016 Directors' Report**

The directors present their annual report and financial statements for Hays Pharma Consulting Limited (the "Company") for the year ended 30 June 2016.

### **Directors**

The current directors and those who served during the year were:

J Harrington (appointed 28 January 2016)


C Stamper (resigned 28 January 2016)

P Venables

### **Registered office**

250 Euston Road  
London  
NW1 2AF

Approved by the Board of Directors and signed on behalf of the Board.

A handwritten signature in black ink, appearing to be 'J Harrington', written over the printed name and title.

J Harrington  
Director

2 November 2016

# Hays Pharma Consulting Limited

## Balance Sheet As at 30 June 2016

	Notes	2016 £	2015 £
<b>Current Assets</b>			
Debtors	4	100	100
<b>Net assets</b>		<u>100</u>	<u>100</u>
<b>Capital and reserves</b>			
Called up share capital	5	100	100
<b>Equity shareholders' funds</b>		<u>100</u>	<u>100</u>


The Company did not trade during the current or previous year and has made neither profit nor loss, nor any other recognised gain or loss.

These accounts have not been audited because the Company is entitled to the exemption provided by Section 480 (1) of the Companies Act 2006 and no notice under Section 476 has been deposited at the Company's registered office requiring the Company to obtain an audit of the accounts.

The directors acknowledge their responsibilities for ensuring that the Company keeps accounting records that comply with Section 386 of the Companies Act 2006. The directors also acknowledge their responsibilities for preparing accounts which give a true and fair view of the state of the Company as at the end of the financial year and of its result for the financial year in accordance with Section 394 of the Companies Act 2006, and which otherwise comply with the requirements of that act relating to accounts, so far as applicable to the Company.

These financial statements of Hays Pharma Consulting Limited, registered number 3500767, were approved by the Board of Directors and authorised for issue on 2 November 2016.

Signed on behalf of the Board of Directors



J Harrington  
Director

# Hays Pharma Consulting Limited

## Notes to the financial statements Year ended 30 June 2016

### 1. Profit and loss account

The Company did not trade and remained dormant throughout the year, therefore no profit and loss account has been presented.

### 2. Accounting policies

#### Basis of accounting

The financial statements are prepared under the historical cost convention and in accordance with applicable accounting standards.

### 3. Directors' emoluments

None of the directors received any remuneration in respect of their services for the year (2015: £nil).

### 4. Debtors

	2016 £	2015 £
Amounts owed by the Parent company	<u>100</u>	<u>100</u>

The amounts owed by the Parent company are repayable on demand. No interest is receivable on the inter-company balance.

### 5. Called up share capital

	2016 £	2015 £
Issued, allotted and fully paid: 1 ordinary share of £1 each	<u>100</u>	<u>100</u>

### 6. Ultimate and immediate parent company

The Company's ultimate parent company and controlling entity is Hays plc, registered in England and Wales. The Company's immediate parent company is Hays Pharma Limited, registered in England and Wales. The parent undertaking of the smallest and largest groups, which include the Company, and for which Group accounts are prepared is Hays plc. Copies of the Report and Accounts of Hays plc are available from the Company Secretary at Hays plc, 250 Euston Road, London NW1 2AF